Lantus Overdose: Case Presentation and Management Options

Journal of Emergency Medicine

Volumn 36, Issue 1, 2009, Pages 26-29

  Fuller, Everett T ^a   Miller, Michael A ^a   Kaylor, David W ^a   Janke, Cliff ^a  

^a CARL R DARNALL ARMY MEDICAL CENTER   (United States)

Author keywords

insulin glargine; Lantus; overdose; suicide

Indexed keywords

GLUCAGON; GLUCOSE; INSULIN GLARGINE; OCTREOTIDE;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CASE REPORT; DRUG OVERDOSE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PRIORITY JOURNAL; SUICIDE ATTEMPT;

ADULT; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INSULIN; MALE; OVERDOSE; SUICIDE, ATTEMPTED; SWEETENING AGENTS;

EID: 58249106084     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jemermed.2007.02.038     Document Type: Article

References (17)

1. Lepore M., Pampanelli S., Fanelli C., et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49 (2000) 2142-2148
2. Tofade T., and Liles E. Intentional overdose with insulin glargine and insulin aspartate. Pharmacotherapy 24 (2004) 1412-1418
3. Green R., and Palatnick W. Effectiveness of octreotide in a case of refractory sulfonylurea-induced hypoglycemia. J Emerg Med 25 (2003) 283-287
4. von Mach M., Meyer S., Omogbehin B., Kann P., and Weilemann L. Epidemiological assessment of 160 cases of insulin overdose recorded in a regional poisons unit. Int J Clin Pharmacol Ther 42 (2004) 277-280
5. Shibutani Y., and Ogawa C. Suicidal insulin overdose in a type 1 diabetic patient: relation of serum insulin concentrations to the duration of hypoglycemia. J Diabetes Complications 14 (2000) 60-62
6. Roberge R., Martin T., and Delbridge T. Intentional massive insulin overdose: recognition and management. Ann Emerg Med 22 (1993) 228-234
7. Samuels M., and Eckel R. Massive insulin overdose: detailed studies of free insulin levels and glucose requirements. J Toxicol Clin Toxicol 27 (1989) 157-168
8. Lantus product insert (2004), Aventis Pharmaceuticals, Bridgewater, NJ
9. Aventis Pharmaceuticals, Inc. Response letter to query for information on pharmacokinetics of insulin glargine. 14 Feb (2005)
10. Pollack C. Utility of glucagon in the emergency department. J Emerg Med 11 (1993) 195-205
11. Love J., and Howell J. Glucagon therapy in the treatment of symptomatic bradycardia. Ann Emerg Med 29 (1997) 181-183
12. Harrigan R., Nathan M., and Beattie P. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. Ann Emerg Med 38 (2001) 68-78
13. Vukmir R., Paris P., and Yealy D. Glucagon: prehospital therapy of hypoglycemia. Ann Emerg Med 20 (1991) 375-379
14. Collier A., Steedman D., Patrick A., et al. Comparison of intravenous glucagon and dextrose in treatment of severe hypoglycemia in an accident and emergency department. Diabetes Care 10 (1987) 712-715
15. Little G., and Boniface K. Are one or two dangerous?. Sulfonylurea exposure in toddlers. J Emerg Med 28 (2005) 305-310
16. McLaughlin S., Crandall C., and McKinney P. Octreotide: an antidote for sulfonylurea-induced hypoglycemia. Ann Emerg Med 36 (2000) 133-138
17. Boyle P., Justice K., Krentz A., Nagy R., and Schade D. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab 76 (2003) 752-756